Showing 1 - 7 results of 7 for search 'Marcel Vetter', query time: 0.03s Refine Results
  1. 1
    Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

    Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges by Marcel Vetter, Markus F. Neurath

    Published 2017-10-01
    Get full text
    Article
  2. 2
    Purple urine in a patient after recovery from a SARS-CoV-2 infection

    Purple urine in a patient after recovery from a SARS-CoV-2 infection by Marcel Vetter, Matthias D. Kaufmann, Markus F. Neurath, Andreas E. Kremer

    Published 2021-04-01
    Get full text
    Article
  3. 3
    The Application of Hemospray in Gastrointestinal Bleeding during Emergency Endoscopy

    The Application of Hemospray in Gastrointestinal Bleeding during Emergency Endoscopy by Alexander F. Hagel, Heinz Albrecht, Andreas Nägel, Francesco Vitali, Marcel Vetter, Christine Dauth, Markus F. Neurath, Martin Raithel

    Published 2017-01-01
    Get full text
    Article
  4. 4
    Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus

    Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus by Miriam M. Düll, Katharina Wolf, Marcel Vetter, Peter Dietrich, Peter Dietrich, Markus F. Neurath, Markus F. Neurath, Andreas E. Kremer

    Published 2021-04-01
    Get full text
    Article
  5. 5
    Risk factors associated with complications of palliative drainage of ascites with tunneled peritoneal catheters

    Risk factors associated with complications of palliative drainage of ascites with tunneled peritoneal catheters by Domenique Machnik, Sarah Fischer, Marcel Vetter, Ricarda Lamprecht-Bailer, Rachel Rouse-Merkel, Daniel Klett, Markus F. Neurath, Deike Strobel, Sebastian Zundler, Sophie Haberkamp

    Published 2025-01-01
    Get full text
    Article
  6. 6
    Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study

    Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort s... by Sarah Fischer, Moritz Donhauser, Sarah Cohnen, Konstantin Fietkau, Marcel Vetter, Maria Grübel-Liehr, Peter Dietrich, Timo Rath, Angelika Wilfer, Ludmilla Sologub, Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya

    Published 2024-11-01
    Get full text
    Article
  7. 7
    Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

    Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections by Alan Bénard, Anne Jacobsen, Maximilian Brunner, Christian Krautz, Bettina Klösch, Izabela Swierzy, Elisabeth Naschberger, Malgorzata J. Podolska, Dina Kouhestani, Paul David, Torsten Birkholz, Ixchel Castellanos, Denis Trufa, Horia Sirbu, Marcel Vetter, Andreas E. Kremer, Kai Hildner, Andreas Hecker, Fabian Edinger, Matthias Tenbusch, Petra Mühl-Zürbes, Alexander Steinkasserer, Enrico Richter, Hendrik Streeck, Marc M. Berger, Thorsten Brenner, Markus A. Weigand, Filip K. Swirski, Georg Schett, Robert Grützmann, Georg F. Weber

    Published 2021-02-01
    Get full text
    Article

Search Tools: